Filtered By:
Condition: Overactive Bladder Syndrome
Countries: Denmark Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
ConclusionsThis large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.
Source: Drug Safety - August 1, 2021 Category: Drugs & Pharmacology Source Type: research
Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study
ConclusionsWe did not identify differences in the risk of cardiovascular events or mortality among users of individual antimuscarinic OAB drugs.
Source: European Journal of Clinical Pharmacology - November 13, 2017 Category: Drugs & Pharmacology Source Type: research
